Oral PCSK9 inhibitor enlicitide lowers LDL cholesterol levels in phase 2 trial.
This phase 2 trial of enlicitide, an oral PCSK9 inhibitor, showed significant LDL cholesterol reduction. As the first oral PCSK9 inhibitor in clinical development, enlicitide could dramatically expand access to advanced lipid-lowering therapy.
Join us
Join the Global Primary Care Cardio Network. Membership is free.
Would you like to tell us more about yourself?
Interests
We will send you an email with a link to confirm your registration.
